United Therapeutics Corporation (FRA:UTH)

Market Cap	17.30B +14.0%
Revenue (ttm)	2.67B +13.5%
Net Income	1.08B +14.5%
EPS	22.48 +16.1%
Shares Out	n/a
PE Ratio	15.96
Forward PE	14.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1
Open	409.00
Previous Close	403.50
Day's Range	409.00 - 409.00
52-Week Range	237.40 - 440.80
Beta	n/a
RSI	54.78
Earnings Date	Feb 25, 2026

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 1,305
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UTH

Financial Performance

In 2024, United Therapeutics's revenue was $2.88 billion, an increase of 23.63% compared to the previous year's $2.33 billion. Earnings were $1.20 billion, an increase of 21.35%.

Financial numbers in USD